05.04.22
Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, has opened its new 45,000 square foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.
Building on years of cell and gene therapy expertise, Matica Bio’s new facility is now expanding its capacity as a CDMO and ready to support the biopharmaceutical industry’s need for faster delivery of cells and viral vectors that are important components of some of the most promising novel therapies.
“The key is faster delivery without sacrificing quality or safety,” said Yun Jeong Song, CEO, Matica Bio. “Our new facility is designed for rapid development, scale-up and production for clinical supply, but our experienced teams provide quality oversight and regulatory guidance necessary to ensure success. Solely committed to our clients’ commercialization goals, we have the expertise and an advanced, modular system that provides the flexibility to adjust resources required depending on client need and product requirements.”
To keep pace with accelerated clinical development time frames, production complexities and demand, Matica Bio already has two collaborations at the new facility. The company is working with Sartorius to develop and optimize advanced viral vector manufacturing technologies for large-scale vector production. Matica Bio has also partnered with Texas A&M University’s Center for Innovation in Advanced Development and Manufacturing for projects to speed up biotech R&D and commercial manufacturing.
“We’re aiming to improve multiple components across the cell and gene therapy production process, including ease of manufacturability, real-time data read-outs, reducing costs and solving anticipated challenges of large-scale cell culture and viral vector production,” said Mike Stewart, chief technology officer, Matica Bio. “These collaborations are just the start of Matica Bio’s commitment for future expansion of research, expertise and successful product development.”
Building on years of cell and gene therapy expertise, Matica Bio’s new facility is now expanding its capacity as a CDMO and ready to support the biopharmaceutical industry’s need for faster delivery of cells and viral vectors that are important components of some of the most promising novel therapies.
“The key is faster delivery without sacrificing quality or safety,” said Yun Jeong Song, CEO, Matica Bio. “Our new facility is designed for rapid development, scale-up and production for clinical supply, but our experienced teams provide quality oversight and regulatory guidance necessary to ensure success. Solely committed to our clients’ commercialization goals, we have the expertise and an advanced, modular system that provides the flexibility to adjust resources required depending on client need and product requirements.”
To keep pace with accelerated clinical development time frames, production complexities and demand, Matica Bio already has two collaborations at the new facility. The company is working with Sartorius to develop and optimize advanced viral vector manufacturing technologies for large-scale vector production. Matica Bio has also partnered with Texas A&M University’s Center for Innovation in Advanced Development and Manufacturing for projects to speed up biotech R&D and commercial manufacturing.
“We’re aiming to improve multiple components across the cell and gene therapy production process, including ease of manufacturability, real-time data read-outs, reducing costs and solving anticipated challenges of large-scale cell culture and viral vector production,” said Mike Stewart, chief technology officer, Matica Bio. “These collaborations are just the start of Matica Bio’s commitment for future expansion of research, expertise and successful product development.”
